Corcept Therapeutics Incorporated. CORT

BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its second-quarter 2026 investor letter for “Buffalo Mid Cap Discovery Fund”. The letter can be downloaded here. The Fund returned 11.34% in the quarter, underperforming its benchmark, the Russell Midcap Growth Index, which returned 14.55%. First-half gains were led by Industrials, Financials, […]

REDWOOD CITY, Calif., September 23, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting Octobe

Corcept Therapeutics (CORT) drew fresh attention after the European Medicines Agency’s CHMP backed approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, following positive Phase 2 and Phase 3 ROSELLA data. Corcept Therapeutics’ latest CHMP backing lands after a powerful run in the share price, with a 90-day share price return of 44.07% and a year to date share price return of 207.60%, while the 5-year total shareholder return of 487.23% points to momentum that...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

On September 18, Corcept Therapeutics (NASDAQ:CORT) said Europe’s drug regulator recommended approval for the cancer therapy that has already earned a spot in US cancer treatment guidelines. The Committee for Medicinal Products for Human Use backed relacorilant, sold in the US as Lifyorli, for use alongside the chemotherapy drug nab-paclitaxel in patients with platinum-resistant ovarian […]

REDWOOD CITY, Calif., September 18, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined w

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 31.6% over the past six months, topping the S&P 500 by 17.9 percentage points.

S&P said on Friday that Bloom Energy, Everpure (P) and Illumina (ILMN) will join the S&P 500 index.

S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.